Cargando…
Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity
Immunostimulatory agents such as agonistic anti-CD137 and interleukin (IL)−2 generate effective anti-tumor immunity but also elicit serious toxicities, hampering their clinical application. Here we show that combination therapy with anti-CD137 and an IL-2-Fc fusion achieves significant initial anti-...
Autores principales: | Zhang, Yuan, Li, Na, Suh, Heikyung, Irvine, Darrell J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750237/ https://www.ncbi.nlm.nih.gov/pubmed/29295974 http://dx.doi.org/10.1038/s41467-017-02251-3 |
Ejemplares similares
-
Systemic delivery of liposome-anchored anti-CD137 and IL2-Fc prevents lethal toxicity and elicits potent antitumor immunity
por: Zhang, Yuan, et al.
Publicado: (2015) -
Co‐Anchoring of Engineered Immunogen and Immunostimulatory Cytokines to Alum Promotes Enhanced‐Humoral Immunity
por: Chang, Jason Y. H., et al.
Publicado: (2022) -
Antigen-Displaying Lipid-Enveloped PLGA Nanoparticles as Delivery Agents for a Plasmodium vivax Malaria Vaccine
por: Moon, James J., et al.
Publicado: (2012) -
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
por: Compte, Marta, et al.
Publicado: (2018) -
Optimization of an alum-anchored clinical HIV vaccine candidate
por: Rodrigues, Kristen A., et al.
Publicado: (2023)